20204-09-12 ミュンヘン大学(LMU)
<関連情報>
- https://www.lmu.de/en/newsroom/news-overview/news/neurodegenerative-diseases-advances-in-diagnosis.html
- https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.14185
アルツハイマー病と4Rタウオパチーのバイオマーカーに基づく層別化のための脳脊髄液とPI-2620タウPETの組み合わせ Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer’s disease and 4R-tauopathies
Roxane Dilcher, Stephan Wall, Mattes Groß, Sabrina Katzdobler, Olivia Wagemann, Carla Palleis, Endy Weidinger, Urban Fietzek, Alexander Bernhardt, Carolin Kurz …
Alzheimer’s & Dementia Published: 12 September 2024
DOI:https://doi.org/10.1002/alz.14185
Abstract
INTRODUCTION
Recent advances in biomarker research have improved the diagnosis and monitoring of Alzheimer’s disease (AD), but in vivo biomarker-based workflows to assess 4R-tauopathy (4RT) patients are currently missing. We suggest a novel biomarker-based algorithm to characterize AD and 4RTs.
METHODS
We cross-sectionally assessed combinations of cerebrospinal fluid measures (CSF p-tau181 and t-tau) and 18F-PI-2620 tau-positron emission tomography (PET) in patients with AD (n = 64), clinically suspected 4RTs (progressive supranuclear palsy or corticobasal syndrome, n = 82) and healthy controls (n = 19).
RESULTS
Elevated CSF p-tau181 and cortical 18F-PI-2620 binding was characteristic for AD while normal CSF p-tau181 with elevated subcortical 18F-PI-2620 binding was characteristic for 4RTs. 18F-PI-2620-assessed posterior cortical hypoperfusion could be used as an additional neuronal injury biomarker in AD.
DISCUSSION
The specific combination of CSF markers and 18F-PI-2620 tau-PET in disease-specific regions facilitates the biomarker-guided stratification of AD and 4RTs. This has implications for biomarker-aided diagnostic workflows and the advancement in clinical trials.
Highlights
- Novel biomarker-based algorithm for differentiating AD and 4R-tauopathies.
- A combination of CSF p-tau181 and 18F-PI-2620 discriminates AD versus 4R tauopathies.
- Hypoperfusion serves as an additional neuronal injury biomarker in AD.
